Ignite Creation Date:
2025-12-24 @ 2:09 PM
Ignite Modification Date:
2026-02-18 @ 11:16 AM
Study NCT ID:
NCT02279095
Status:
COMPLETED
Last Update Posted:
2025-02-19
First Post:
2014-10-26
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)
Sponsor:
Clementia Pharmaceuticals Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Fibrodysplasia Ossificans Progressiva | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Open-label extension study | View |
| None | Clinical trial Phase 2 | View |
| None | Efficacy and safety | View |
| None | Heterotopic ossification | View |
| None | Fibrodysplasia Ossificans Progressiva | View |
| None | Flare-up | View |
| None | Palovarotene | View |
| None | Retinoic acid receptor agonist | View |
| None | Retinoic acid receptor gamma agonist | View |
| None | Clementia | View |
| None | Myositis Ossificans Progressiva | View |
| None | Munchmeyer's Disease | View |
| None | FOP | View |
| None | Ipsen | View |